GETNE Registration of Thyroid Cancer
Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic
1 other identifier
observational
20
1 country
1
Brief Summary
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 20, 2018
CompletedFirst Posted
Study publicly available on registry
December 5, 2018
CompletedStudy Start
First participant enrolled
May 28, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedOctober 3, 2024
October 1, 2024
6.5 years
November 20, 2018
October 2, 2024
Conditions
Outcome Measures
Primary Outcomes (4)
Hystopathological characteristics of the tumor
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Baseline
Situation of the tumor at first-diagnosis
Local tumor, locoregional tumor or metastatic disease.
Baseline
Tumor-Node-Metastasis classification
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Baseline
Tumor Stage
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Baseline
Secondary Outcomes (8)
Patient situation at the end of treatment
12 months
Number of patients with BRAF mutation
12 months
Number of patients with RET mutation
12 months
Number of patients with PI3K mutation
12 months
Number of patients with RAS mutation
12 months
- +3 more secondary outcomes
Eligibility Criteria
Patients ≥ 18 years visited in the oncology services of the participating centers that have a diagnosis of primary cancer located in the thyroid gland.
You may qualify if:
- Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology.
- Patients who agree to participate and are able to understand the information sheet and sign the informed consent
You may not qualify if:
- Patients under 18 years of age.
- Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed.
- Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Universitari Vall d'Hebron
Barcelona, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jorge Hernando Cubero, M.D.
Hospital Universitari Vall d'Hebron, Barcelona
- STUDY CHAIR
Jaume Capdevila, M.D.
Hospital Universitari Vall d'Hebron, Barcelona
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 20, 2018
First Posted
December 5, 2018
Study Start
May 28, 2019
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
October 3, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share